NCT02555397View on ClinicalTrials.gov

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 16, 2019

Study Completion Date

January 22, 2024

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Ad5-yCD/mutTKSR39rep-hIL12

Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1

Trial Locations (1)

40202

Henry Ford Health System, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT02555397 - Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter